Daxor Corporation announces the expansion of blood volume analysis through new analyzer purchases and the utilization of Daxor’s ezBVA Lab service. These Q4 2023 initiatives have all played a significant role in driving the growth and the widespread adoption of BVA providing a strong position going into 2024. Q4-2023 sales wins include: BVA analyzer purchase at the largest and most integrated healthcare system in Georgia; BVA analyzer purchase at a community-directed health system based in Wisconsin; BVA analyzer rental at an academic health center servicing patients from Oregon, southwest Washington, Idaho, Montana, Alaska, and northern California; Daxor’s ezBVA Lab service extended to an additional site in a 17-hospital healthcare organization in New Jersey.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DXR:
